Key Highlights

  • Immunome shares traded at $22.16, down 0.72% on the day.
  • Phase 1 dosing commenced for 177Lu-IM-3050, noted July 20, 2026.
  • 177Lu-IM-3050 is described as an immunotherapy candidate.
  • Immunome's market capitalization stands at approximately $2.51 billion.

Immunome Inc. (NASDAQ: IMNM) shares traded at $22.16, down 0.72% on the day, after the company disclosed that Phase 1 dosing has commenced for its immunotherapy candidate 177Lu-IM-3050.

What Happened

The dosing commencement was noted July 20, 2026, according to the disclosed pipeline database.

Market Reaction

Shares traded down 0.72% at $22.16, with Immunome's market capitalization at approximately $2.51 billion, according to the disclosed information.

Outlook

The disclosed information does not include additional detail on the trial design or expected data timeline for 177Lu-IM-3050 beyond the commencement of dosing.

What did Immunome disclose about 177Lu-IM-3050?

Phase 1 dosing has commenced for the immunotherapy candidate, noted July 20, 2026.

What type of candidate is 177Lu-IM-3050?

It is described as an immunotherapy candidate.

What is Immunome's current market capitalization?

Approximately $2.51 billion, according to the disclosed pipeline database.